United States Follicular Thyroid Cancer Drug Market 2025 | Growth Drivers, Competitive Landscape & Business Opportunities

Market Size and Growth

The Follicular Thyroid Cancer Drug Market is predicted to reach at a high CAGR during the forecast period (2023-2030).

Key Development:

United States: Recent Industry Developments

✅ In June 2025, Memorial Sloan Kettering Cancer Center (MSK) reported promising results from a clinical trial using larotrectinib as a first-line treatment for NTRK-positive thyroid cancers. Nearly 90% of tumors shrank significantly, with about 75% of patients alive after five years, highlighting the potential of targeted therapies in FTC management.

✅ In March 2025, the FDA granted Breakthrough Therapy Designation to cabozantinib (Cabometyx) for patients with advanced, radioiodine-refractory differentiated thyroid cancer. This designation aims to expedite the development and review of the drug, potentially offering a new treatment option for patients with limited alternatives.

Japan: Recent Industry Developments

✅ In August 2025, Teijin Pharma received approval for YORVIPATH® (parathyroid hormone) in Japan, a treatment for hypoparathyroidism. This development reflects Japan's ongoing efforts to address rare endocrine disorders, which can be associated with thyroid conditions.

✅ In March 2025, Chugai Pharmaceutical launched LUNSUMIO® (mosunetuzumab), a bispecific antibody for relapsed or refractory follicular lymphoma in Japan. While primarily targeting lymphoma, its approval underscores Japan's commitment to advancing treatments for follicular cell-related cancers.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/follicular-thyroid-cancer-drug-market?sb

Follicular thyroid cancer drugs are therapeutic agents used to treat follicular thyroid cancer, a type of differentiated thyroid cancer. These drugs include targeted therapies, radioactive iodine, and chemotherapeutic agents that help inhibit tumor growth, manage metastasis, and improve patient outcomes by acting on cancerous thyroid cells while minimizing damage to healthy tissue.

Recent Mergers and acquisitions:

United States: Recent M&A Developments

✅ In January 2025, GSK announced its acquisition of IDRx for $1.15 billion. This strategic move enhances GSK's precision kinase portfolio, complementing its work in thyroid cancer therapies.

✅ In January 2025, Lantheus Holdings agreed to acquire Evergreen Theragnostics for $1 billion. This acquisition secures radioligand manufacturing capacity, bolstering Lantheus's capabilities in thyroid cancer diagnostics and treatment.

Japan: Recent M&A Developments

✅ In June 2025, ESTEVE entered into an agreement with Sanofi to acquire Caprelsa® (vandetanib) rights in more than 50 countries. This acquisition allows ESTEVE to expand its rare disease portfolio by including a treatment for medullary thyroid cancer.

Key Players:

=> AstraZeneca, GlaxoSmithKline Plc, Novartis AG, Merck & Co, Pfizer Inc, Exelixis Inc, Celgene Corporation, Bayer AG, Eisai Co., Ltd, Teva Pharmaceuticals.

Growth Forecast Projected:

The Global Follicular Thyroid Cancer Drug Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Follicular Thyroid Cancer Drug Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=follicular-thyroid-cancer-drug-market

Key Segments:

➥ By Drug Type: Cabozantinib, Lenvatinib and Sorafenib, Selpercatinib, Larotrectinib and Entrectinib, Others

➥ By Treatment Type: Surgery, Radioactive Iodine Drugs, External Beam Radiotherapy, Thyroxin Treatment, Chemotherapy

➥ By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others

Regional Analysis for Follicular Thyroid Cancer Drug Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Follicular Thyroid Cancer Drug producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Follicular Thyroid Cancer Drug revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/follicular-thyroid-cancer-drug-market?sb

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.